The prognostic and therapeutic potential of vimentin in colorectal cancer.
Colorectal cancer
Prognostic marker
Therapeutic target
Vimentin
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
15
06
2024
accepted:
20
09
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
epublish
Résumé
Several cells and molecules in the tumor microenvironment have been introduced as effective factors in the prognosis and progression of colorectal cancer. As a key element of the intermediate filament family, vimentin is expressed by mesenchymal cells in a ubiquitous manner and contributes significantly to cellular integrity and stress resistance in colorectal cancer. Recent studies have shown that alterations in the expression patterns of intermediate filaments are significantly related to cancer progression, especially in phenotypes associated with cellular migration and invasion. In addition to its multiple biological roles, vimentin also has a substantial function in mediating the epithelial-mesenchymal transition. Therefore, evaluating vimentin as an effective factor involved in the prognosis of colorectal cancer and targeting it as a novel approach to cancer therapy have become one of the main goals of many researchers worldwide. In this article, we will review the various biological functions of vimentin, as well as its relationship with colorectal cancer with the aim of providing novel insights into its clinical importance in the prognosis and treatment of colorectal cancer.
Identifiants
pubmed: 39347868
doi: 10.1007/s11033-024-09965-w
pii: 10.1007/s11033-024-09965-w
doi:
Substances chimiques
Vimentin
0
Biomarkers, Tumor
0
VIM protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1027Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12–49
doi: 10.3322/caac.21820
Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
doi: 10.3322/caac.21492
Naxerova K et al (2017) Origins of lymphatic and distant metastases in human colorectal cancer. Science 357(6346):55–60
pmcid: 5536201
doi: 10.1126/science.aai8515
Bajpai P et al (2024) Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer. J Exp Clin Cancer Res 43(1):192
pmcid: 11238352
doi: 10.1186/s13046-024-03106-8
Lin YM et al (2021) Image-guided ablation for colorectal liver metastasis: principles, current evidence, and the path Forward. Cancers (Basel), 13(16)
Azadi A et al (2021) Recent advances on Immune targeted therapy of Colorectal Cancer using bi-specific antibodies and therapeutic vaccines. Biol Proced Online 23(1):13
pmcid: 8245152
doi: 10.1186/s12575-021-00147-7
Bosma NA et al (2021) Efficacy of perioperative chemotherapy in resected colorectal liver metastasis: a systematic review and meta-analysis. Eur J Surg Oncol
Kwan J, Pua U (2021) Review of intra-arterial therapies for Colorectal Cancer Liver Metastasis. Cancers (Basel), 13(6)
Golkhalkhali B et al (2018) The roles of adjuvant supplements in Colorectal Cancer patients on chemotherapy - reaping benefits from metabolic crosstalk. Nutr Cancer 70(2):184–191
doi: 10.1080/01635581.2018.1412470
Aquilani R et al (2024) Chemotherapy-Induced changes in plasma amino acids and lipid oxidation of Resected patients with colorectal Cancer: a background for Future studies. Int J Mol Sci, 25(10)
Lee HY, Woo IS (2021) Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates. Cancers (Basel), 13(18)
Koulouris A et al (2021) Resectable Colorectal Cancer: current perceptions on the correlation of recurrence risk, microbiota and detection of genetic mutations in Liquid biopsies. Cancers (Basel), 13(14)
Haria PD et al (2021) Follow-up of colorectal cancer and patterns of recurrence. Clin Radiol
Holle AW et al (2017) Intermediate filament reorganization dynamically influences cancer cell alignment and migration. Sci Rep 7:45152
pmcid: 5364536
doi: 10.1038/srep45152
Prieto-García E et al (2017) Epithelial-to-mesenchymal transition in tumor progression. Med Oncol 34(7):122
doi: 10.1007/s12032-017-0980-8
Chida K et al (2024) Gastric cancer with enhanced myogenesis is associated with less cell proliferation, enriched epithelial-to-mesenchymal transition and angiogenesis, and poor clinical outcomes. Am J Cancer Res 14(1):355–367
pmcid: 10839307
doi: 10.62347/NCIM3072
Zhang Y, Weinberg RA (2018) Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med 12(4):361–373
pmcid: 6186394
doi: 10.1007/s11684-018-0656-6
Nieto MA et al (2016) EMT: 2016. Cell 166(1):21–45
doi: 10.1016/j.cell.2016.06.028
Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9(4):265–273
doi: 10.1038/nrc2620
Catalanotto M et al (2024) Dual role of CASP8AP2/FLASH in regulating epithelial-to-mesenchymal transition plasticity (EMP). Transl Oncol 39:101837
doi: 10.1016/j.tranon.2023.101837
Chen Y et al (2024) Genetic tracing uncovers the importance of epithelial-to-mesenchymal transition in small cell lung cancer chemotherapy resistance but not metastasis. Cell Discov 10(1):60
pmcid: 11150244
doi: 10.1038/s41421-024-00687-8
Majc B et al (2020) Epithelial-to-mesenchymal transition as the driver of changing carcinoma and glioblastoma microenvironment. Biochim Biophys Acta Mol Cell Res 1867(10):118782
doi: 10.1016/j.bbamcr.2020.118782
Ahmadiankia N, Khosravi A (2020) Significance of epithelial-to-mesenchymal transition inducing transcription factors in predicting distance metastasis and survival in patients with colorectal cancer: a systematic review and meta-analysis. J Res Med Sci 25:60
pmcid: 7554549
doi: 10.4103/jrms.JRMS_174_19
Noetzel E et al (2010) Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the synemin gene is associated with early tumor relapse. Oncogene 29(34):4814–4825
doi: 10.1038/onc.2010.229
Monteiro-Reis S et al (2023) Vimentin epigenetic deregulation in bladder Cancer associates with acquisition of invasive and metastatic phenotype through epithelial-to-mesenchymal transition. Int J Biol Sci 19(1):1–12
pmcid: 9760433
doi: 10.7150/ijbs.77181
Ho Thanh MT et al (2024) Vimentin Promotes Collective cell Migration through Collagen Networks via Increased Matrix Remodeling Spheroid Fluidity bioRxiv
Pan Y et al (2010) [Role of vimentin in tumor metastasis and drug research]. Sheng Li Ke Xue Jin Zhan 41(6):413–416
Brzozowa M et al (2015) The aberrant overexpression of vimentin is linked to a more aggressive status in tumours of the gastrointestinal tract. Prz Gastroenterol 10(1):7–11
pmcid: 4411408
Xu CY et al (2016) NIBP impacts on the expression of E-cadherin, CD44 and vimentin in colon cancer via the NF-κB pathway. Mol Med Rep 13(6):5379–5385
doi: 10.3892/mmr.2016.5165
Hemalatha A, Suresh TN, Kumar ML (2013) Expression of vimentin in breast carcinoma, its correlation with Ki67 and other histopathological parameters. Indian J Cancer 50(3):189–194
doi: 10.4103/0019-509X.118724
Hu L et al (2004) Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 23(1):298–302
doi: 10.1038/sj.onc.1206483
Liu PF et al (2017) Vimentin is a potential prognostic factor for tongue squamous cell carcinoma among five epithelial-mesenchymal transition-related proteins. PLoS ONE 12(6):e0178581
pmcid: 5453552
doi: 10.1371/journal.pone.0178581
Liu S et al (2016) High vimentin expression Associated with Lymph Node Metastasis and predicated a poor prognosis in oral squamous cell carcinoma. Sci Rep 6:38834
pmcid: 5155220
doi: 10.1038/srep38834
Said R et al (2023) Correlation between E-cadherin/β-catenin, vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: a molecular and clinical study. Genesis, : p. e23543
Bronte G et al (2021) The interplay between programmed death Ligand 1 and Vimentin in Advanced Non-small-cell Lung Cancer. Front Oncol 11:669839
pmcid: 8130554
doi: 10.3389/fonc.2021.669839
Ancel J et al (2019) Programmed death-ligand 1 and Vimentin: a Tandem marker as prognostic factor in NSCLC. Cancers (Basel), 11(10)
Liang Y et al (2024) Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma. Biochim Biophys Acta Mol Cell Res 1871(7):119781
doi: 10.1016/j.bbamcr.2024.119781
Yao JX et al (2020) Prognostic value of vimentin is Associated with Immunosuppression in metastatic renal cell carcinoma. Front Oncol 10:1181
pmcid: 7417332
doi: 10.3389/fonc.2020.01181
Toiyama Y et al (2013) Increased expression of slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis 34(11):2548–2557
doi: 10.1093/carcin/bgt282
Wang Q et al (2021) Vimentin affects colorectal cancer proliferation, invasion, and migration via regulated by activator protein 1. J Cell Physiol
Li Q et al (2019) RUNX1 promotes tumour metastasis by activating the Wnt/β-catenin signalling pathway and EMT in colorectal cancer. J Exp Clin Cancer Res 38(1):334
pmcid: 6670220
doi: 10.1186/s13046-019-1330-9
Cai HK et al (2017) MicroRNA-194 modulates epithelial-mesenchymal transition in human colorectal cancer metastasis. Onco Targets Ther 10:1269–1278
pmcid: 5338959
doi: 10.2147/OTT.S125172
Chang N et al (2021) Long noncoding RNA LINC00857 promotes proliferation, Migration, and Invasion of Colorectal Cancer cell through miR-1306/Vimentin Axis. Comput Math Methods Med 2021:p5525763
doi: 10.1155/2021/5525763
Qi L et al (2014) Wnt3a expression is associated with epithelial-mesenchymal transition and promotes colon cancer progression. J Exp Clin Cancer Res 33(1):107
pmcid: 4269867
doi: 10.1186/s13046-014-0107-4
Wang Y et al (2017) NUBPL, a novel metastasis-related gene, promotes colorectal carcinoma cell motility by inducing epithelial-mesenchymal transition. Cancer Sci 108(6):1169–1176
pmcid: 5480060
doi: 10.1111/cas.13243
Gu Y et al (2016) TUSC3 promotes colorectal cancer progression and epithelial-mesenchymal transition (EMT) through WNT/β-catenin and MAPK signalling. J Pathol 239(1):60–71
doi: 10.1002/path.4697
Ngan CY et al (2007) Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer 96(6):986–992
pmcid: 2360104
doi: 10.1038/sj.bjc.6603651
Satelli A et al (2016) Potential function of exogenous vimentin on the activation of wnt signaling pathway in Cancer cells. J Cancer 7(13):1824–1832
pmcid: 5039366
doi: 10.7150/jca.15622
Vermani L et al (2020) Expression pattern of ALDH1, E-cadherin, Vimentin and twist in early and late onset sporadic colorectal cancer. Biomark Med 14(14):1371–1382
doi: 10.2217/bmm-2020-0206
Xiao S et al (2015) The prognostic significance of bromodomain PHD-finger transcription factor in colorectal carcinoma and association with vimentin and E-cadherin. J Cancer Res Clin Oncol 141(8):1465–1474
doi: 10.1007/s00432-015-1937-y
Yang Y et al (2017) Repressor activator protein 1-promoted colorectal cell migration is associated with the regulation of Vimentin. Tumour Biol 39(4):1010428317695034
doi: 10.1177/1010428317695034
Ostrowska-Podhorodecka Z et al (2023) Vimentin-mediated myosin 10 aggregation at tips of cell extensions drives MT1-MMP-dependent collagen degradation in colorectal cancer. Faseb j 37(8):e23097
doi: 10.1096/fj.202300672R
Yu J et al (2023) Evaluation of cell surface vimentin positive circulating tumor cells as a prognostic biomarker for stage III/IV colorectal cancer. Sci Rep 13(1):18791
pmcid: 10620146
doi: 10.1038/s41598-023-45951-1
Al-Maghrabi J (2020) Vimentin immunoexpression is associated with higher tumor grade, metastasis, and shorter survival in colorectal cancer. Int J Clin Exp Pathol 13(3):493–500
pmcid: 7137029
Yun JA et al (2014) Loss of E-Cadherin expression is associated with a poor prognosis in stage III colorectal cancer. Oncology 86(5–6):318–328
doi: 10.1159/000360794
Du L et al (2018) High vimentin expression predicts a poor prognosis and progression in Colorectal Cancer: a study with Meta-analysis and TCGA database. Biomed Res Int 2018:p6387810
doi: 10.1155/2018/6387810
Zhou B et al (2021) High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors. BMC Cancer 21(1):334
pmcid: 8010952
doi: 10.1186/s12885-021-08062-6
Myoteri D et al (2017) Prognostic evaluation of Vimentin expression in correlation with Ki67 and CD44 in surgically resected pancreatic ductal adenocarcinoma. Gastroenterol Res Pract 2017:p9207616
doi: 10.1155/2017/9207616
Nakashima H et al (2015) Prevalent and up-regulated vimentin expression in micropapillary components of lung adenocarcinomas and its adverse prognostic significance. Pathol Int 65(4):183–192
doi: 10.1111/pin.12257
Yin S, Chen FF, Yang GF (2018) Vimentin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis. Pathol Res Pract 214(9):1376–1380
doi: 10.1016/j.prp.2018.07.014
Chakraborty S et al (2019) Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model. Cell Death Dis 10(6):467
pmcid: 6565729
doi: 10.1038/s41419-019-1690-2
Hong SN (2018) Genetic and epigenetic alterations of colorectal cancer. Intest Res 16(3):327–337
pmcid: 6077299
doi: 10.5217/ir.2018.16.3.327
Ayers D, Boughanem H, Macías-González M (2019) Epigenetic influences in the Obesity/Colorectal Cancer Axis: a Novel Theragnostic Avenue. J Oncol 2019:p7406078
doi: 10.1155/2019/7406078
Tomicic MT, Dawood M, Efferth T (2021) Epigenetic alterations upstream and downstream of p53 signaling in Colorectal Carcinoma. Cancers (Basel), 13(16)
Anghel SA et al (2021) Promising epigenetic biomarkers for the early detection of Colorectal Cancer: a systematic review. Cancers (Basel), 13(19).
Puccini A et al (2017) Colorectal cancer: epigenetic alterations and their clinical implications. Biochim Biophys Acta Rev Cancer 1868(2):439–448
doi: 10.1016/j.bbcan.2017.09.003
Rodriguez-Casanova A et al (2021) Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer. Front Cell Dev Biol 9:622459
pmcid: 7892964
doi: 10.3389/fcell.2021.622459
Shirahata A et al (2009) Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res 29(1):279–281
Gerecke C et al (2015) Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is increased in inflamed colon tissue: putative risk markers for colitis-associated cancer. J Cancer Res Clin Oncol 141(12):2097–2107
doi: 10.1007/s00432-015-1972-8
Shirahata A et al (2010) Detection of vimentin (VIM) methylation in the serum of colorectal cancer patients. Anticancer Res 30(12):5015–5018
Song BP et al (2012) Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J Mol Diagn 14(2):112–119
pmcid: 3349838
doi: 10.1016/j.jmoldx.2011.12.003
Pakbaz B et al (2019) Quantitative study of vimentin gene methylation in stool samples for colorectal cancer screening. J Adv Pharm Technol Res 10(3):121–125
pmcid: 6621348
doi: 10.4103/japtr.JAPTR_381_18
Shirahata A, Hibi K (2014) Serum vimentin methylation as a potential marker for colorectal cancer. Anticancer Res 34(8):4121–4125
Zou H et al (2007) Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev 16(12):2686–2696
doi: 10.1158/1055-9965.EPI-07-0518
Zhu W et al (2019) MicroRNA-34a suppresses the invasion and migration of colorectal cancer cells by enhancing EGR1 and inhibiting vimentin. Exp Ther Med 18(4):2459–2466
pmcid: 6755272
Kim TW et al (2020) MicroRNA-17-5p regulates EMT by targeting vimentin in colorectal cancer. Br J Cancer 123(7):1123–1130
pmcid: 7524803
doi: 10.1038/s41416-020-0940-5
Biondi A et al (2024) Extracellular vesicles and Immune System function: exploring Novel approaches to Colorectal Cancer Immunotherapy. Biomedicines, 12(7)
Chuang L, Qifeng J, Shaolei Y (2024) The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer. Discov Oncol 15(1):244
pmcid: 11199466
doi: 10.1007/s12672-024-01117-7
Kamrani A et al (2024) New Immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses. Cell Commun Signal 22(1):56
pmcid: 10799490
doi: 10.1186/s12964-023-01430-8
Arroyo-Olarte R, Mejía-Muñoz A, León-Cabrera S (2024) Expanded Alternatives of CRISPR-Cas9 Applications in Immunotherapy of Colorectal Cancer. Mol Diagn Ther 28(1):69–86
doi: 10.1007/s40291-023-00680-z
Jin H et al (2021) Intratumorally CpG immunotherapy with carbon nanotubes inhibits local tumor growth and liver metastasis by suppressing the epithelial-mesenchymal transition of colon cancer cells. Anticancer Drugs 32(3):278–285
doi: 10.1097/CAD.0000000000001000
Ohara M et al (2020) Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer. Cancer Immunol Immunother 69(6):989–999
pmcid: 11027720
doi: 10.1007/s00262-020-02524-9
McInroy L, Määttä A (2007) Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun 360(1):109–114
doi: 10.1016/j.bbrc.2007.06.036
Bao Y et al (2019) COUP–TFII promotes epithelial–mesenchymal transition by inhibiting miR–34a expression in colorectal cancer. Int J Oncol 54(4):1337–1344
Wang B et al (2014) miR-29b suppresses tumor growth and metastasis in colorectal cancer via downregulating Tiam1 expression and inhibiting epithelial-mesenchymal transition. Cell Death Dis 5(7):e1335
pmcid: 4123095
doi: 10.1038/cddis.2014.304
Tang W et al (2020) MicroRNA–500a–5p inhibits colorectal cancer cell invasion and epithelial–mesenchymal transition. Int J Oncol 56(6):1499–1508
Ning X et al (2019) Ectopic expression of miR-147 inhibits stem cell marker and epithelial-mesenchymal transition (EMT)-Related protein expression in Colon cancer cells. Oncol Res 27(4):399–406
pmcid: 7848281
doi: 10.3727/096504018X15179675206495
Li Q et al (2016) Mir-139-5p inhibits the epithelial-mesenchymal transition and enhances the chemotherapeutic sensitivity of Colorectal Cancer cells by downregulating BCL2. Sci Rep 6:27157
pmcid: 4886683
doi: 10.1038/srep27157
Bartha Á, Győrffy B (2021) TNMplot.com: a web Tool for the comparison of Gene expression in normal, Tumor and metastatic tissues. Int J Mol Sci, 22(5)
Chandrashekar DS et al (2017) UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19(8):649–658
pmcid: 5516091
doi: 10.1016/j.neo.2017.05.002
Shannon P et al (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–2504
pmcid: 403769
doi: 10.1101/gr.1239303
Kuleshov MV et al (2016) Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44(W1):W90–W97
pmcid: 4987924
doi: 10.1093/nar/gkw377
Ru B et al (2019) TISIDB: an integrated repository portal for tumor–immune system interactions. Bioinformatics 35(20):4200–4202
doi: 10.1093/bioinformatics/btz210
Freshour SL et al (2021) Integration of the drug–gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res 49(D1):D1144–D1151
doi: 10.1093/nar/gkaa1084